Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.

Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

Survival and new cancers with myeloproliferative neoplasms.

Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.